SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-21-244745
Filing Date
2021-08-12
Accepted
2021-08-12 16:27:31
Documents
72
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q d148717d10q.htm   iXBRL 10-Q 1727800
2 EX-31.1 d148717dex311.htm EX-31.1 9361
3 EX-31.2 d148717dex312.htm EX-31.2 9352
4 EX-32.1 d148717dex321.htm EX-32.1 5168
  Complete submission text file 0001193125-21-244745.txt   6163645

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tpst-20210630.xsd EX-101.SCH 45078
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tpst-20210630_cal.xml EX-101.CAL 33824
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20210630_def.xml EX-101.DEF 202851
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20210630_lab.xml EX-101.LAB 403996
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20210630_pre.xml EX-101.PRE 322847
10 EXTRACTED XBRL INSTANCE DOCUMENT d148717d10q_htm.xml XML 804480
Mailing Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35890 | Film No.: 211167972
SIC: 2834 Pharmaceutical Preparations